# Genevoyager

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/genevoyager

- Industry: Biotechnology
- Headquarters: Wuhan, China
- Website: www.genevoyager.ltd
- Latest round: Series A (Aug 29, 2023)
- Investors on record: 2

## About

Based in Wuhan, China, and established in 2022, Genevoyager is a biotechnology company that engages in the development of large-scale viral vector production and delivery technology. The company also is a one-stop contract research organization (CRO) or contract development and manufacturing organization (CDMO) service for gene therapy drugs. The company's R&D team members with master's and doctoral degrees account for 70% of employees. The company has two multiple subsidiaries, BrainVTA (Wuhan) Co., Ltd., a CRO company providing customized viral packing services over the past 9 years. The other subsidiary, Reingene (Wuhan) Co., Ltd., a CDMO company,  can produce large-scale Adeno-associated viruses AAV gene therapy drugs. In August 2023, Genevoyager raised strategic investment led by new investor SDIC Venture Capital, with participation from other new investor Homsun Capital.

The company provides CRO services, including one-stop services for new drug non-clinical evaluation, drug screening,  Adeno-associated viruses (AAV) service, oncolytic viruses services, stem cell services, and protein and VLP services. The company also provides CDMO services, including AAV CDMO services, cell banking, virus seed banking, AAV non-GMP production, AAV-GMP production, oncolytic virus modification, and protein or virus-like particles (VLP) CDMO services. The company also has technology platforms, including one Bac 4.0 system, molecular cloning and screening platforms, animal disease model construction platforms, and neutralizing antibody detection platforms.

## Funding rounds

- Series A, Aug 29, 2023 — Homsun Capital, SDIC Venture Capital

## Investors

- Homsun Capital (https://capitalatlas.ai/funds/homsun-capital) — Series A
- SDIC Venture Capital (https://capitalatlas.ai/funds/sdic-venture-capital) — Series A